期刊文献+

EGFP标记的A20细胞构建小鼠B细胞播散型淋巴瘤模型

Establishment of a Disseminated Model of Mouse B-Cell Lymphoma with A20 Cell Lines Expression Enhanced Green Fluorescent Protein
原文传递
导出
摘要 目的:A20细胞是来源于同系Balb/c小鼠大B细胞淋巴瘤的细胞系,能通过尾静脉接种建立小鼠B细胞播散型淋巴瘤的模型,但由于该细胞系缺乏细胞表面特异性标志而难于监测。本研究使用增强型绿色荧光蛋白(EGFP)标记A20细胞,试图建立易于监测的小鼠B细胞播散型淋巴瘤模型。方法:用含增强型绿色荧光蛋白(EGFP)的慢病毒载体将标记基因EGFP转入A20细胞,通过流式分选出EGFP+的A20细胞,体外培养后通过尾静脉注射接种于同系Balb/c小鼠体内,用流式细胞仪监测其外周血EGFP+细胞的百分率。当小鼠出现消瘦、毛发竖立、嗜睡等体征时,将小鼠处以安乐死;取动物脏器行石蜡包埋、病理切片、HE染色。结果:尾静脉注射1×106细胞于6只Balb/c小鼠体内,接种后15天可在外周血中检测到EGFP+细胞,平均生存时间为29.6±0.8天;在肝脏、脾脏、脊椎和淋巴结等多脏器成瘤,流式检测瘤细胞EGFP表达阳性。结论:经尾静脉注射接种A20细胞可建立小鼠B细胞播散型淋巴瘤模型,A20细胞经含EGFP的慢病毒标记后易于通过流式进行监测,为通过动物体内试验评价靶向治疗的疗效提供了保证。 Objective: The A20 cells are B lymphocytes from a syngeneic Balb/c mouse with a large B-cell lymphoma, and a disseminated model of mouse B-cell lymphoma can be established by using A20 cell line via tail vein injection. The model was hard to monitor because of no specific cell surface markers. Our study is to present a disseminated model of mouse B-cell lymphoma easy to be monitored by using A20 cells labled with EGFP. Methods: A20 cells were transfected with a lentivirus vector containing a gene encoding enhanced green fluorescent protein (EGFP), EGFP+A20 cells were sorted by FACS and intravenously injected into syngeneic Balb/c mouse, and the percentage of EGFP± cells were evaluated by flow cytometry. The mice were euthanized at the first indication of morbidity (weight loss, ruffed fur, lethargy). Organs were paragon-imbedded, sectioned and analyzed by microscopy. Results: 1× 10^6 cells were inoculated into 6 Balb/c mouse via tail vein injection, EGFP± cells in peripheral blood were detected 15 days post inoculation. The average time of survival was 29.6 ± 0.8 days. Organs such as liver, spleen, spine and lymph nodes were involved, while flow cytometry showed the tumor cells were positive for EGFP. Conclusion: A disseminated model of mouse B-cell lymphoma can be established by using A20 cell line via tail vein injection, which was easy to be traced after transfection of A20 cells with a lentivirus vector containing a gene encoding enhanced green fluorescent protein (EGFP), providing a useful experimental platform for further in vivo target therapy researches.
出处 《现代生物医学进展》 CAS 2014年第25期4801-4805,共5页 Progress in Modern Biomedicine
基金 国家自然科学基金项目(81200380)
关键词 淋巴瘤 模型 A20 流式细胞术 增强型绿色荧光蛋白 Lymphoma Model A20 Flow cytometry Enhanced green fluorescent protein
  • 相关文献

参考文献6

二级参考文献89

  • 1张宁,脱帅,刘秋珍,杨波,王明耀,朱希伟.人肝恶性淋巴瘤裸小鼠原位和皮下移植模型的建立及生物学特性的研究[J].消化外科,2006,5(1):57-61. 被引量:5
  • 2刘秋珍,脱朝伟,张宁,杨波,朱希伟,王明耀.人原发性直肠恶性淋巴瘤裸小鼠原位移植模型的建立及其生物学特性[J].消化外科,2006,5(3):206-210. 被引量:10
  • 3刘秋珍,脱朝伟,张宁,杨波,王承利.人原发性结肠恶性淋巴瘤裸小鼠原位移植肝转移模型的建立[J].中华胃肠外科杂志,2006,9(4):323-327. 被引量:4
  • 4孙琦,陈辉树.恶性淋巴瘤的病因学研究进展[J].国际输血及血液学杂志,2006,29(5):398-402. 被引量:20
  • 5Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007 [J]. CA Cancer J Clin, 2007,57:43-66.
  • 6Shipp MA, Harrington DP, Anderson JR, et al. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project [J]. N Engl J Med, 1993,329:987-994.
  • 7Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: An Italian multicenter randomized trial [J]. J Clin Oncol, 2003,21(7):1255-1262.
  • 8Gisselbrecht C, Lepage E, Molina T, et al. Shortened firstline high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma [J]. J Clin Oncol, 2002,20(10):2472- 2479.
  • 9van Imhoff GW, van der Holt B, Mackenzie MA, et al. Impact of three courses of intensified CHOP prior to highdose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-Hodgkin's lymphoma: Comparative analysis of Duch-Belgian hemato-oncology cooperative group studies 27 and 40 [J]. J Clin Oncol, 2005,23 (16) : 3793-3801.
  • 10Greb A, Bohlius J, Schiefer D, et al. High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive non-Hodgkin lymphoma(NHL) in adults [DB/CD]. Cochrane Database Syst Rev, 2008,23 (1): CD004024.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部